ArticleWorld journal of surgical oncology2026
The value of hysterectomy in the management of gestational trophoblastic neoplasia: a retrospective analysis.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundWhile chemotherapy is central to gestational trophoblastic disease (GTD) management, concerns over toxicity and resistance have renewed interest in hysterectomy. This study evaluated outcomes of patients treated with hysterectomy, focusing on histopathology, chemotherapy use, and survival.
methodsA retrospective analysis was performed on consecutive eligible patients undergoing hysterectomy for GTD from 2014 to 2023. Data on demographics, surgery indications, chemotherapy, and follow-up were collected and analyzed.
resultsAmong 96 GTD patients undergoing hysterectomy, the timing of surgery was a key determinant of treatment intensity. Patients who underwent first-line hysterectomy (n = 34) required significantly fewer chemotherapy cycles to achieve remission than those needing surgery after failed chemotherapy (non-first-line hysterectomy) (median: 2 [IQR: 1–4] vs. 7 [IQR: 5–9] cycles; P <0.001). This benefit was most evident in low-risk patients (WHO score 0–6), where primary surgery alone achieved cure in selected cases, thereby reducing or eliminating chemotherapy exposure. Hysterectomy was also definitive for chemoresistant histologies (placental site trophoblastic tumor and epithelioid trophoblastic tumor). The overall survival rate was 95% for the gestational trophoblastic neoplasia cohort.
conclusionsThis study demonstrates that first-line hysterectomy significantly reduces postoperative chemotherapy requirements for patients with GTD, particularly in the low-risk subgroup. These findings support integrating timely surgical intervention into risk-adapted treatment algorithms to de-escalate systemic therapy while maintaining high survival rates. For patients with chemoresistant histologies, hysterectomy remains a definitive therapeutic option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.